CBN Market Report
The full U.S. CBN market — measured retail data, modeled extrapolation, consumer demand evidence, and unit economics across every channel that sells it.
Presented by FloraWorks · June 2026
9
Demand evidence
Consumers are buying for outcomes
Five recent studies, surveying more than 200,000 people combined, highlight that dispensary consumers are shopping for benefits like sleep, pain relief, anxiety, and stress. The line between recreational use and wellness has effectively dissolved for the majority of the cannabis-buying population. CBN sits at the center of this transition as consumers actively seek an effective alternative sleep aid.
Edibles consumers — Cannabis Science and Technology, 2025⁵
76.1%
JAMA Network Open, 2024
Of 175,734 cannabis users in a primary care study reported using cannabis to manage a health symptom — even when they identified as recreational users.¹
13%
NuggMD, 2024 (n=6,550)
Only 13% say recreation is their main goal. Pain relief (25%), anxiety relief (23%), and stress relief (18%) all rank higher.²
98.8%
MoreBetter (n=2,500)
Of THC beverage drinkers select at least one wellness reason for drinking. One in three select only wellness reasons.³
22M
National Sleep Foundation, 2025
U.S. adults currently use a cannabis product as a sleep aid. 60 million say they would try one.⁴
13
From Modeled to Measured
Category Analytics
The analysis that follows is all built on retail point-of-sale data captured at licensed dispensaries across 15 legal recreational markets sourced from Headset analytics, which pulls sales records straight from dispensary cash registers rather than from surveys or brand reports.
How Headset Collects Data⁶
The Headset Methodology
15 Markets Measured
AZ, CA, CO, CT, IL, MD, MA, MI, MO, NV, NJ, NY, OH, OR, WA — every state where Headset captures CBN-level metadata.
3,000+ Connected Retailers
Cannabis retailers contributing point-of-sale data into the panel across all measured markets.
Government Totals + Retailer POS
Combines state-reported sales totals with statistically sampled retailer point-of-sale data.
State-Regulator Reconciliation
Product-level forecasts reconciled up to match each state's regulator totals for accuracy.
Standardized Product Taxonomy
Apples-to-apples comparison across markets, brands, and categories through unified classification.
85–90% Revenue Coverage
Of total U.S. adult-use cannabis revenue inside the 15-market panel is captured.
Q1 2021 → Q1 2026
Five years of continuous retail observation underwrites every trend in this report.
3,000+ Retailers in Real-Time
Headset connects directly to point-of-sale systems at more than 3,000 cannabis retailers across the US and Canada. Over $1 billion in retail sales moves through the platform every month. Major brands and multi-state operators use it for category planning.
Classified by Cannabinoid
We classified every edible SKU in the dataset by labeled cannabinoid content. "CBN edibles" includes any product listing CBN as an active ingredient, alone or in ratios. Prices are item-level. For each state, we draw on the full licensed recreational dataset.
Future CBN Products
Where the Next Portfolio SKU Should Land
Higher CBN Per Package — Dosed to the Science
SKUs anchored at 100mg or more of CBN per package are growing at an average of 220% — roughly 3.5× faster than older lower-dose flagships are declining. Kanha's Sleep Marionberry Plum, the highest-CBN product on this list at 150mg per package, posted the strongest growth in the cohort at +550%. The next move is to translate package dose into per-serving dose that aligns with the clinical evidence, where 25mg per serving is the baseline at which sleep improvements have been measured. A 250mg CBN package at 25mg per serving is the sweet spot the data and the science both point toward.
Multi-Cannabinoid as a Perceived-Value Lever
The fastest-growing SKUs aren't single-ingredient products. They stack CBN with CBG, CBC, or CBD inside one formulation. Wana's top product carries four cannabinoids; Incredibles and Wana both anchor with CBN and CBG together. The clinical evidence on specific multi-cannabinoid ratios is still developing — but the consumer response isn't waiting. Multi-cannabinoid formulations signal value-add and layered functional benefits that resonate strongly with today's sleep-focused consumer.
The Signal Is Clear
The category's growth is concentrated in the SKUs that deliver more — more total cannabinoid content, more CBN specifically, and more functional ingredients working together. Two of the five top brands posted 400%-plus growth in their high-dose multi-cannabinoid flagship while their older single-purpose SKUs contracted by half. This is the highest-growth product format in the category, and the gap between old-generation and new-generation performance is widening.
THE PATH FORWARD
TruCBN™: The clinically-validated, regulatory-ready CBN ingredient built for the next generation of wellness brands
This report has documented a billion-dollar CBN category built almost entirely inside regulated cannabis and hemp retail — but the next leg of growth lives outside those channels, among the consumers already shopping the supplement aisle for melatonin, magnesium, and alternative sleep aids. The mainstream supplement market reaches consumers cannabis and hemp brands cannot. TruCBN™ is the ingredient that gets brands there. The plan below is the same four steps whether you're a cannabis operator extending into mainstream retail or a supplement brand entering the CBN category for the first time.
This is the path for unlocking new CBN consumers:
1
Today's Channels
Where CBN has built into a billion-dollar category: regulated cannabis dispensaries and hemp retail. Proven consumer demand and durable pricing power — but together these channels reach only a fraction of the U.S. CBN opportunity.
2
TruCBN™ is the Gateway
The clinically validated, regulatory-ready CBN ingredient credentialed to enter the dietary supplement channel — built specifically to make this crossover possible where ordinary CBN cannot follow.
3
The New Channel
Mainstream supplement retail: natural grocers, vitamin chains, mass wellness aisles, and the DTC brands consumers already trust for sleep. The shelf where melatonin lives — and where CBN is the science-backed alternative consumers are quietly migrating toward.
4
Expanded Market Access
A consumer base several times the size of today's cannabis-and-hemp CBN audience: older, more affluent, already shopping the supplement aisle, and actively looking for an alternative to melatonin. This is where CBN graduates from category to mass-market ingredient.
27
About FloraWorks
Built for operators serious about minor cannabinoids
FloraWorks supplies CBN, CBG, THCV, and CBC to over 100 cannabis and hemp brands across the U.S. The team has been working in minor cannabinoids since the early days of the category — manufacturing built to GMP standards, documentation built for state-level audits, and a portfolio that lets brands consolidate their supply rather than chase four different vendors.
The reason any of this matters isn't the science on its own. It's the people the science reaches. CBN is one of the most studied cannabinoids in the wellness conversation, and the category data in this report shows that real consumers are finding real value in it.FloraWorks' job is to make sure the brands building those products can do so with ingredients they trust, paperwork that holds up, and a supplier that picks up the phone.
Compliance footprint
Hemp and cannabinoid licenses in:
- Oregon · Colorado · Michigan · California · New York
- Manufacturing partners covering Massachusetts and Pennsylvania
Full QMS documentation
FloraWorks maintains a quality management system covering material specifications, batch records, and audit-ready compliance documentation across every state of operation.
Download our QMS Document
Download our QMS Document
Get in touch
Talk to us about sourcing minor cannabinoids for your brand.
